Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

MacTel Laser Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03321916
Recruitment Status : Recruiting
First Posted : October 26, 2017
Last Update Posted : February 27, 2019
Sponsor:
Information provided by (Responsible Party):
The Lowy Medical Research Institute Limited

Brief Summary:
This is a two armed Single Masked Pilot Study enrolling participants with Macular Telangiectasia Type 2 who will be randomized to undergo either a subthreshold photothermal treatment or a sham procedure to one eye. The participants will be followed for one year with visits at 1 month, 3 months, 6 months and 12 months post-treatment (laser or sham). Due to the small number of participants enrolled in this study the data will be analyzed by descriptive statistics and exploratory figures. Summary statistics will be produced for study and fellow eyes.

Condition or disease Intervention/treatment Phase
Macular Telangiectasia Device: 577-nm PASCAL laser Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Controlled Pilot Study for Safety and Efficacy of Subthreshold Photothermal Therapy for Patients With Macular Telangiectasia (MacTel) Type 2
Actual Study Start Date : February 8, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: Subthreshold Photothermal Therapy Device: 577-nm PASCAL laser
The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.

Sham Comparator: Sham Device: 577-nm PASCAL laser
The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 3 months post treatment ]
    To evaluate the safety and tolerability of subthreshold photothermal therapy in patients with MacTel Type 2 as assessed by CTCAE v4.0


Secondary Outcome Measures :
  1. Change from baseline cone density as measured by confocal adaptive optics (AOSLO) [ Time Frame: 1 year ]
    To evaluate the biological activity of subthreshold photothermal therapy in patients with MacTel Type 2.

  2. Change in size of ellipsoid zone break area as measured by spectral domain optical coherence tomography (SD-OCT) [ Time Frame: 1 year ]
    To evaluate the biological activity of subthreshold photothermal therapy in patients with MacTel Type 2.

  3. Development or extension post therapy of areas of deficiency in cones as measured by AOSLO [ Time Frame: 1 year ]
    To evaluate the biological activity of subthreshold photothermal therapy in patients with MacTel Type 2.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed and dated written informed consent obtained from the participant in accordance with the local regulations;
  2. Males/females 21 years of age and older but less than 80 years of age;
  3. Participant must have a positive diagnosis of MacTel Type 2 in at least one eye with evidence of fluorescein leakage typical of MacTel or at least one of the other features including loss of retinal transparency/hyper-reflectivity to blue light, crystalline deposits, right angle vessels, inner/outer retinal low-reflective spaces, or hyperpigmentation not involving the center of the fovea, but no evidence of intraretinal/subretinal vascular proliferation;
  4. Participant must have an Ellipsoid Zone (EZ, aka IS/OS) break in the study eye between 0.16 - 4.0 mm2 as measured on SD-OCT;
  5. Participant's best-corrected visual acuity at least 55 letters (20/80) in the study eye;
  6. Participant must have steady fixation in the foveal or parafoveal area of each eye, adequate pupil dilation and sufficiently clear media to perform multi-modal retinal imaging and treatment;
  7. Participant must be able and willing to attend all scheduled visits.

    For Participants undergoing optional AOSLO imaging:

  8. Participant should have reproducible baseline AOSLO image montages at 2 baseline imaging sessions with quality suitable to identify a minimum of 7 regions of interest (ROIs) at which reliable cone spacing measures can be made in each eye.

Exclusion Criteria:

  1. Participant is unable to provide informed consent;
  2. Participant is less than 21 years of age or greater than 80 years of age; (but less than 80);
  3. Participant is medically unable to comply with study procedures or follow-up visits;
  4. Participant received intravitreal therapy for non-neovascular MacTel in the study eye and in the fellow eye, injections no sooner than 3 months prior to study treatment;
  5. Participant has nystagmus in either eye;
  6. Participant has greater than 7 diopters myopia in either eye;
  7. Participant has been diagnosed and treated for amblyopia in the study eye;
  8. Participant has significant ocular abnormalities in either eye that prevent retinal assessment, including media opacities or cataract (up to Nuclear Sclerosis +1 is allowable);
  9. Participant was a study participant in any other clinical trial of an intervention (drug or device) within the last 6 months;
  10. Participant has a history of malignancy that would compromise the 12 month study survival; or
  11. Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the patient's risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments;
  12. Presence of signs of advanced retinal/vascular disease in the study eye, such as CNV, haemorrhages or macular atrophy based on OCT or FAF;
  13. Previous macular laser treatment in either eye;
  14. Any previous ocular condition that may be associated with a risk of developing macular oedema;
  15. Vitreomacular traction determined clinically and/or by OCT, which in the opinion of the investigator contributes to the macular oedema (associated or causing a detachment of the fovea) in the study eye;
  16. Presence of other macular disease such as epiretinal membrane in the study eye;
  17. Ocular or periocular infections;
  18. Planned intra-ocular surgery in the study eye within one year; and
  19. Patient is unavailable for follow-up visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03321916


Contacts
Layout table for location contacts
Contact: Jennifer Trombley, MSN 858-249-7109 JTrombley@LMRI.net
Contact: Martin Friedlander, MD, PhD 858-249-7100 MFriedlander@LMRI.net

Locations
Layout table for location information
United States, Wisconsin
Medical College of Wisconsin & Froedtert Hospital Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Eleanor Dorsey    414-955-7854    edorsey@mcw.edu   
Contact: David Weinberg, MD    414-955-7840    dweinber@mcw.edu   
Principal Investigator: David Weinberg, MD         
Sponsors and Collaborators
The Lowy Medical Research Institute Limited

Layout table for additonal information
Responsible Party: The Lowy Medical Research Institute Limited
ClinicalTrials.gov Identifier: NCT03321916     History of Changes
Other Study ID Numbers: MacTelLaser1
First Posted: October 26, 2017    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by The Lowy Medical Research Institute Limited:
MacTel

Additional relevant MeSH terms:
Layout table for MeSH terms
Telangiectasis
Vascular Diseases
Cardiovascular Diseases